Nicholas Glover - 01 Jul 2021 Form 4 Insider Report for MEI Pharma, Inc. (MEIP)

Role
Director
Signature
/s/ Brian G. Drazba, as attorney in fact
Issuer symbol
MEIP
Transactions as of
01 Jul 2021
Net transactions value
$0
Form type
4
Filing time
06 Jul 2021, 18:59:25 UTC
Next filing
07 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MEIP Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 01 Jul 2021 Common Stock 50,000 $2.95 Direct F1
holding MEIP Stock Option (Right to Buy) 20,000 01 Jul 2021 Common Stock 20,000 $1.57 Direct F2
holding MEIP Stock Option (Right to Buy) 40,000 01 Jul 2021 Common Stock 40,000 $1.36 Direct F2
holding MEIP Stock Option (Right to Buy) 40,000 01 Jul 2021 Common Stock 40,000 $2.83 Direct F2
holding MEIP Stock Option (Right to Buy) 40,000 01 Jul 2021 Common Stock 40,000 $4.28 Direct F2
holding MEIP Stock Option (Right to Buy) 40,000 01 Jul 2021 Common Stock 40,000 $2.52 Direct F2
holding MEIP Stock Option (Right to Buy) 50,000 01 Jul 2021 Common Stock 50,000 $3.49 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest in equal monthly installments over twelve months.
F2 All of such options are presently exercisable.